Matrix metalloproteinases: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease

Current Pharmaceutical Design

Volumn 13, Issue 17, 2007, Pages 1787-1802

  Arroyo, A G ^a   Genis L ^a   Gonzalo, P ^a   Matias Roman S ^a   Pollan A ^a   Galvez B G ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Angiogenesis; Endothelial cells; Inflammation; Matrix remodelling; MTI MMP; Therapy

Indexed keywords

BATIMASTAT; DOXYCYCLINE; ENZYME ANTIBODY; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 14 ANTIBODY; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN RECK; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ARTERY DISEASE; ARTHRITIS; ASCITES; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CANCER; CAVERNOUS HEMANGIOMA; CHRONIC HEPATITIS; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIGEORGE SYNDROME; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EMPHYSEMA; ENDOMETRIOSIS; ENDOTHELIUM CELL; ENTERITIS; ENZYME SUBSTRATE; FRACTURE NONUNION; GENE THERAPY; HAIR LOSS; HUMAN; HYPERTENSION; INFECTION; KAPOSI SARCOMA; KELOID; KIDNEY DISEASE; LUNG FIBROSIS; MENORRHAGIA; MOUTH ULCER; MULTIPLE SCLEROSIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; NOSE POLYP; OBESITY; OSTEOMYELITIS; OSTEOPOROSIS; OVARY CYST; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PERITONEUM ADHESION; PERSISTENT HYPERPLASTIC PRIMARY VITREOUS; PREECLAMPSIA; PRIORITY JOURNAL; PSORIASIS; PULMONARY HYPERTENSION; PURPURA; REGULATORY MECHANISM; RENDU OSLER WEBER DISEASE; RESTENOSIS; RETROLENTAL FIBROPLASIA; REVIEW; RNA INTERFERENCE; SCAR FORMATION; SKIN ALLERGY; SPONDYLOSIS; STOMACH ULCER; STROKE; SUBRETINAL NEOVASCULARIZATION; SYNOVITIS; TELANGIECTASIA; UTERUS BLEEDING; VERRUCA VULGARIS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; ENDOTHELIAL CELLS; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34250849091     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831284     Document Type: Review

References (217)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
4. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
5. Tallquist MD, Soriano P, Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 1999; 18: 7917-32.
6. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
7. Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol 2001; 13: 202-8.
8. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608.
9. Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-107.
10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
11. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411-24.
12. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol 2003; 54: 1-74.
13. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-40.
14. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
15. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267-85.
16. Kraling BM, Wiederschain DG, Boehm T, Rehn M, Mulliken JB, Moses MA. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J Cell Sci 1999; 112: 1599-609.
17. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-70.
18. Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci 1999; 112: 1283-90.
19. Yan L, Moses MA, Huang S, Ingber DE. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci 2000; 113: 3979-87.
20. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
21. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
22. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 2000; 97: 12227-32
23. Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: Absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res 2005; 65: 9377-87.
24. Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 2001; 262: 28-36.
25. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem 1998; 273: 5400-4.
26. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002; 160: 673-80.
27. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35-48.
28. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993; 296: 803-9.
29. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
30. Plaisier M, Kapiteijn K, Koolwijk P, Fijten C, Hanemaaijer R, Grimbergen JM, et al. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: Role of MT3-MMP. J Clin Endocrinol Metab 2004; 89: 5828-36.
31. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 2003; 114: 171-80.
32. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-15.
33. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-51.
34. Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 2003; 17: 2290-2.
35. Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci 2003; 44(1): 403-8.
36. Ohno-Matsui K, Uetama T, Yoshida T, Hayano M, Itoh T, Morita I, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci 2003; 44: 5370-5.
37. Sarman S, van der Ploeg I, Seregard S, Kvanta A. Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. Curr Eye Res 2005; 30: 259-67.
38. Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005; 80: 159-66.
39. Takahashi M, Fukami S, Iwata N, Inoue K, Itohara S, Itoh H, et al. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol Res 2002; 46: 155-63
40. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411-22.
41. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
42. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64: 1675-86.
43. Gagne PJ, Tihonov N, Li X, Glaser J, Qiao J, Silberstein M, et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 2005; 167: 1349-59.
44. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase- 9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ Res 2004; 94: 262-8.
45. Hangai M, Kitaya N, Xu J, Chan CK, Kim JJ, Werb Z, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002; 161: 1429-37.
46. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 290: H232-9.
47. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002; 21: 272-81.
48. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
49. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-8.
50. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001; 276: 37491-500.
51. Galvez BG, Genis L, Matias-Roman S, Oblander SA, Tryggvason K, Apte SS, et al. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/ CXCL8 in endothelial cells during angiogenesis. J Biol Chem 2005; 280: 1292-8.
52. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998; 273: 3604-10.
53. Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG. ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 2002; 159: 509-21.
54. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99: 81-92.
55. Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97: 4052-7.
56. Oblander SA, Zhou Z, Galvez BG, Starcher B, Shannon JM, Durbeej M, et al. Distinctive functions of membrane type 1 matrixmetalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. Dev Biol 2005; 277: 255-69.
57. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004; 167: 757-67
58. Lehti K, Allen E, Birkedal-Hansen H, Holmbeck K, Miyake Y, Chun TH, et al. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev 2005; 19: 979-91.
59. Filippov S, Koenig GC, Chun TH, Hotary KB, Ota I, Bugge TH, et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 2005; 202: 663-71.
60. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003; 22: 8716-22.
61. Sounni NE, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279: 13564-74.
62. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002; 157: 493-507.
63. Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H, et al. Matrix metalloproteinases (MMPs) regulate fibrininvasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 2002; 195: 295-308.
64. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004; 167: 769-81.
65. Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J. Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinasedependent melanoma cell invasion. Cancer Res 2006; 66: 248-58.
66. Seiki M, Mori H, Kajita M, Uekita T, Itoh Y. Membrane-type 1 matrix metalloproteinase and cell migration. Biochem Soc Symp 2003; (70): 253-62.
67. Langlois S, Gingras D, Beliveau R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 2004; 103: 3020-8.
68. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-24.
69. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114: 33-45.
70. Golubkov VS, Boyd S, Savinov AY, Chekanov AV, Osterman AL, Remacle A, et al. Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem 2005; 280: 25079-86.
71. Golubkov VS, Chekanov AV, Doxsey SJ, Strongin AY. Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: Potential implications for tumorigenesis. J Biol Chem 2005; 280: 42237-41.
72. Robinet A, Fahem A, Cauchard JH, Huet E, Vincent L, Lorimier S, et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci 2005; 118: 343-56.
73. Polette M, Gilles C, Nawrocki-Raby B, Lohi J, Hunziker W, Foidart JM, et al. Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Cancer Res 2005; 65: 7691-8.
74. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today 2003; 69: 272-85.
75. Langlois S, Di Tomasso G, Boivin D, Roghi C, Murphy G, Gingras D, et al. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res 2005; 307: 452-64.
76. Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 1999; 274: 22679-85.
77. Mace KA, Hansen SL, Myers C, Young DM, Boudreau N. HOXA3 induces cell migration in endothelial and epithelial cells promoting angiogenesis and wound repair. J Cell Sci 2005; 118: 2567-77.
78. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11: 2387-401.
79. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27
80. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003; 22: 55-61.
81. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
82. Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 2006; 25(30): 4230-4.
83. Hsu MC, Chang HC, Hung WC. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 2006; 281: 4718-25.
84. Galvez BG, Matias-Roman S, Yanez-Mo M, Vicente-Manzanares M, Sanchez-Madrid F, Arroyo AG. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 2004; 15: 678-87.
85. Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-59
86. Annabi B, Lachambre M, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001; 353: 547-53.
87. Labrecque L, Nyalendo C, Langlois S, Durocher Y, Roghi C, Murphy G, et al. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 2004; 279: 52132-40.
88. Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, Pei D. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci USA 2001; 98: 13693-8.
89. Uekita T, Itoh Y, Yana I, Ohno H, Seiki M. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001; 155: 1345-56
90. Remacle A, Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003; 116: 3905-16.
91. Remacle AG, Rozanov DV, Baciu PC, Chekanov AV, Golubkov VS, Strongin AY. The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP). J Cell Sci 2005; 118: 4975-84.
92. Wang X, Ma D, Keski-Oja J, Pei D. Co-recycling of MT1-MMP and MT3-MMP through the trans-Golgi network. Identification of DKV582 as a recycling signal. J Biol Chem 2004; 279: 9331-6.
93. Wang P, Wang X, Pei D. Mint-3 regulates the retrieval of the internalized membrane-type matrix metalloproteinase, MT5-MMP, to the plasma membrane by binding to its carboxyl end motif EWV. J Biol Chem 2004; 279: 20461-70.
94. Takino T, Miyamori H, Kawaguchi N, Uekita T, Seiki M, Sato H. Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Commun 2003; 304: 160-6.
95. Rozanov DV, Deryugina EI, Monosov EZ, Marchenko ND, Strongin AY. Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Exp Cell Res 2004; 293: 81-95.
96. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001; 20: 4782-93.
97. Rozanov DV, Deryugina EI, Ratnikov BI, Monosov EZ, Marchenko GN, Quigley JP, et al. Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. J Biol Chem 2001; 276: 25705-14.
98. Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J. Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem 2002; 277: 8440-8.
99. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, et al. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem 2002; 277: 26340-50.
100. Toth M, Osenkowski P, Hesek D, Brown S, Meroueh S, Sakr W, et al. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem J 2005; 387: 497-506.
101. Wu YI, Munshi HG, Sen R, Snipas SJ, Salvesen GS, Fridman R, et al. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem 2004; 279: 8278-89.
102. Anilkumar N, Uekita T, Couchman JR, Nagase H, Seiki M, Itoh Y. Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J 2005; 19: 1326-8.
103. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005; 19: 234-6.
104. Matias-Roman S, Galvez BG, Genis L, Yanez-Mo M, de la Rosa G, Sanchez-Mateos P, et al. Membrane type 1-matrix metalloprote inase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 2005; 105: 3956-64.
105. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
106. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation 2005; 112: 1813-24.
107. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein Edeficient mice. Circulation 1999; 99: 1726-32.
108. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-41.
109. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6: 112-20.
110. Mezzetti A. Pharmacological modulation of plaque instability. Lupus 2005; 14: 769-72.
111. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-9.
112. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-9.
113. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, et al. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000; 41: 82-8.
114. Graesser D, Mahooti S, Haas T, Davis S, Clark RB, Madri JA. The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab Invest 1998; 78: 1445-58.
115. Graesser D, Mahooti S, Madri JA. Distinct roles for matrix metalloproteinase- 2 and alpha4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 109: 121-31.
116. Esparza J, Kruse M, Lee J, Michaud M, Madri JA. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. Faseb J 2004; 18: 1682-91.
117. Kirk S, Frank JA, Karlik S. Angiogenesis in multiple sclerosis: Is it good, bad or an epiphenomenon? J Neurol Sci 2004; 217: 125-30.
118. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
119. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-12.
120. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-60.
121. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999; 103: 47-54.
122. Stupack DG, Storgard CM, Cheresh DA. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res 1999; 32: 573-81.
123. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005; 17: 578-83.
124. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5: 285-98.
125. Whelan CJ. Metalloprotease inhibitors as anti-inflammatory agents: An evolving target? Curr Opin Investig Drugs 2004; 5: 511-6.
126. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2002; 2: 255-71.
127. Puerta DT, Cohen SM. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Top Med Chem 2004; 4: 1551-73.
128. Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)SARs results. Curr Med Chem 2005; 12: 339-55.
129. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
130. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005; 87: 249-63.
131. Borkakoti N. Matrix metalloprotease inhibitors: Design from structure. Biochem Soc Trans 2004; 32: 17-20.
132. Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1999; 878: 61-72.
133. Ryan ME, Ramamurthy S, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996; 3: 85-96.
134. Daheshia M. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Curr Med Res Opin 2005; 21: 587-94.
135. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-31.
136. Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH. Matrix metalloproteinases: A therapeutic target in cardiovascular disease. Curr Pharm Des 2003; 9: 1033-40.
137. Elliott S, Cawston T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging 2001; 18: 87-99.
138. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-50.
139. Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, Morrison CJ, et al. Protease degradomics: Mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 2004; 385: 493-504.
140. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998; 17: 5238-48.
141. Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J. SDR grafting--a new approach to antibody humanization. Methods 2005; 36: 25-34.
142. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005; 579: 5996-6007.
143. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 117-42
144. Lu PY, Xie FY, Woodle MC. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med 2005; 11: 104-13.
145. Nonaka T, Nishibashi K, Itoh Y, Yana I, Seiki M. Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 in vivo. Mol Cancer Ther 2005; 4: 1157-66.
146. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-72.
147. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci USA 2004; 101: 6917-22.
148. Hwang IK, Park SM, Kim SY, Lee ST. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim Biophys Acta 2004; 1702: 79-87.
149. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, et al. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 2005; 24: 4124-32
150. Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, et al. VEGF: A modifier of the del22q11 (DiGeorge) syndrome? Nat Med 2003; 9: 173-82.
151. Sadick H, Naim R, Gossler U, Hormann K, Riedel F. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 2005; 15: 15-9.
152. Sure U, Butz N, Schlegel J, Siegel AM, Wakat JP, Mennel HD, et al. Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. J Neurosurg 2001; 94: 972-7.
153. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998; 39: 8-33.
154. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997; 811: 191-206.
155. Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T, Ishigai Y, et al. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res 2001; 52: 314-20.
156. Humpert PM, Eichler H, Lammert A, Hammes HP, Nawroth PP, Bierhaus A. Adult vascular progenitor cells and tissue regeneration in metabolic syndrome. Vasa 2005; 34: 73-8, 80.
157. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB. Co-accumulation of vascular endothelial growth factor with betaamyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 2004; 25: 283-90.
158. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-7.
159. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23: 117-45.
160. Luttun A, Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies. Curr Atheroscler Rep 2000; 2: 407-16.
161. Szekanecz Z, Gaspar L, Koch AE. Angiogenesis in rheumatoid arthritis. Front Biosci 2005; 10: 1739-53.
162. Ross JJ. Angiogenic gene therapy as a potential therapeutic agent in chronic osteomyelitis. Med Hypotheses 2006; 67: 161-163
163. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003; 48: 2173-7.
164. Hiltunen MO, Ruuskanen M, Huuskonen J, Mahonen AJ, Ahonen M, Rutanen J, et al. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J 2003; 17: 1147-9.
165. Hausman MR, Schaffler MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 2001; 29: 560-4.
166. Leong TT, Fearon U, Veale DJ. Angiogenesis in psoriasis and psoriatic arthritis: Clues to disease pathogenesis. Curr Rheumatol Rep 2005; 7: 325-9.
167. Harada K, Lu S, Chisholm DM, Syrjanen S, Schor AM. Angiogenesis and vasodilation in skin warts. Association with HPV infection. Anticancer Res 2000; 20: 4519-23.
168. Groneberg DA, Bester C, Grutzkau A, Serowka F, Fischer A, Henz BM, et al. Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy 2005; 60: 90-7.
169. Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol 2004; 50: 850-3.
170. Brown LF, Harrist TJ, Yeo KT, Stahle-Backdahl M, Jackman RW, Berse B, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol 1995; 104: 744-9.
171. Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord 2003; 3: 115-28.
172. Simonetti O, Lucarini G, Bernardini ML, Simoncini C, Biagini G, Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: An immunohistochemical study. Br J Dermatol 2004; 150: 940-8.
173. Topaloglu R, Sungur A, Baskin E, Besbas N, Saatci U, Bakkaloglu A. Vascular endothelial growth factor in Henoch-Schonlein purpura. J Rheumatol 2001; 28: 2269-73.
174. Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, Fidler IJ. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 1998; 111: 864-72.
175. Hatoum OA, Binion DG, Gutterman DD. Paradox of simultaneous intestinal ischaemia and hyperaemia in inflammatory bowel disease. Eur J Clin Invest 2005; 35: 599-609.
176. Chapple CC, Kumar RK, Hunter N. Vascular remodelling in chronic inflammatory periodontal disease. J Oral Pathol Med 2000; 29: 500-6
177. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 2000; 50: 217-24.
178. Thaler K, Mack JA, Berho M, Grotendorst G, Wexner SD, Abramson SR. Coincidence of connective tissue growth factor expression with fibrosis and angiogenesis in postoperative peritoneal adhesion formation. Eur Surg Res 2005; 37: 235-41.
179. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-95.
180. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50(Suppl 1): S24-33.
181. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-18.
182. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001; 107: 295-301.
183. Coste A, Brugel L, Maitre B, Boussat S, Papon JF, Wingerstmann L, et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 2000; 15: 367-72.
184. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002; 8: 702-10.
185. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol 2005; 25: 429-63.
186. Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: Evidence that angiogenesis participates in alveolarization. Circulation 2005; 112: 2477-86.
187. McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 2002; 99: 3848-53.
188. Favard C, Ortega N, Bayard F, Plouet J. Vascular endothelial growth factor and retinal neovascularisation: A new therapeutic approach for diabetic retinopathy. Diabetes Metab 1996; 22: 268-73.
189. Hutcheson KA. Retinopathy of prematurity. Curr Opin Ophthalmol 2003; 14: 286-90.
190. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: A need for balanced expressions. Clin Biochem 2006; 39: 267-76.
191. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-54.
192. Girling JE, Rogers PA. Recent advances in endometrial angiogenesis research. Angiogenesis 2005; 8: 89-99.
193. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update 2002; 8: 60-7.
194. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003; 162: 1881-93.
195. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255-6
196. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
197. Kang DH, Johnson RJ. Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003; 12: 43-9.
198. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-51
199. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem 2005; 280: 88-93.
200. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-7.
201. Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, et al. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 1999; 340: 171-81.
202. Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, et al. An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem 2002; 277: 7377-85.
203. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001; 153: 893-904.
204. Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, Strongin AY. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001; 276: 18415-22.
205. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-8.
206. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002; 100: 1160-7.
207. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003; 278: 40764-70.
208. Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, et al. Cleavage of metastasis suppressor gene product KiSS-1 protein/ metastin by matrix metalloproteinases. Oncogene 2003; 22: 4617-26.
209. Holopainen JM, Moilanen JA, Sorsa T, Kivela-Rajamaki M, Tervahartiala T, Vesaluoma MH, et al. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003; 44: 2550-6.
210. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124-31.
211. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MTMMPs). J Cell Sci 2002; 115: 3427-38.
212. Collen A, Hanemaaijer R, Lupu F, Quax PH, van Lent N, Grimbergen J, et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101: 1810-7.
213. Parmo-Cabanas M, Molina-Ortiz I, Matias-Roman S, Garcia-Bernal D, Carvajal-Vergara X, Valle I, et al. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol 2005; 208: 108-18
214. Bartolome RA, Galvez BG, Longo N, Baleux F, Van Muijen GN, Sanchez-Mateos P, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534-43.
215. Butler GS, Overall CM. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr Pharm Des 2007; 13(3): 263-70.
216. Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: Present status and perspectives. Curr Pharm Des 2007; 13(1): 17-31.
217. Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 2006; 12(21): 2645-60